Loading...

enVVeno Medical Corporation

NVNOWNASDAQ
HealthcareMedical - Devices
$0.006
$-0.00(-32.98%)

enVVeno Medical Corporation (NVNOW) Stock Overview

Explore enVVeno Medical Corporation’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
0.00%
Profit Growth
$-1.05
7.22%
EPS Growth
$-1.05
33.51%
Operating Margin
-2866.63%
5.59%
ROE
-51.32%
7.22%
Dividend Yield
0.00%
Analyst Recommendations data is not available for NVNOWAnalyst Recommendations details for NVNOW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

CEO

Mr. Robert A. Berman

Employees

30

Headquarters

70 Doppler, Irvine, CA

Founded

2018

Frequently Asked Questions